HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Episode of harmful use of synthetic cannabinoid — Clinical Guidelines

Overview

Episode of harmful use of synthetic cannabinoids refers to acute intoxication resulting from the misuse of synthetic cannabinoids, often marketed as legal alternatives to marijuana. These substances, designed to mimic the effects of THC, can produce severe and unpredictable psychoactive and physiological effects due to their high potency and varied chemical compositions. Clinically significant due to their potential to cause acute psychosis, severe agitation, cardiovascular complications, and even fatalities, these episodes disproportionately affect young adults and vulnerable populations such as incarcerated individuals and those with a history of substance misuse. Recognizing and managing these episodes is crucial in day-to-day practice to mitigate acute risks and prevent long-term harm. 3 15

Pathophysiology

Synthetic cannabinoids exert their effects primarily through agonism of cannabinoid receptors, predominantly CB1 receptors found abundantly in the central nervous system (CNS). Unlike natural cannabinoids like THC, synthetic cannabinoids often exhibit higher affinity and potency for these receptors, leading to exaggerated and potentially toxic responses. This heightened activity can disrupt normal neurotransmitter functions, particularly affecting areas involved in pain modulation, mood regulation, and cognitive processes. The resultant dysregulation can manifest as acute psychotic symptoms, severe anxiety, and cardiovascular stress, including tachycardia and hypertension. Additionally, the variability in chemical structures among synthetic cannabinoids contributes to unpredictable pharmacological profiles, complicating their clinical presentation and management. 3 7 17

Epidemiology

The incidence of harmful use of synthetic cannabinoids has risen significantly since their emergence in the early 2000s, particularly among younger populations and marginalized groups such as incarcerated individuals and homeless populations. These substances are often marketed as legal highs, attracting users seeking novel psychoactive experiences. Geographic trends show higher prevalence in regions with less stringent drug control policies or where traditional illicit drug markets are saturated. Prevalence data vary widely, but studies suggest a notable increase in reports of synthetic cannabinoid-related emergencies in emergency departments across multiple countries over recent years. Risk factors include prior substance use disorders, mental health issues, and socio-economic vulnerabilities. 3 2 15

Clinical Presentation

Typical presentations include acute onset of symptoms such as agitation, hallucinations, tachycardia, hypertension, and altered mental status ranging from confusion to frank psychosis. Atypical presentations might involve severe anxiety attacks, seizures, or cardiovascular collapse. Red-flag features include severe agitation unresponsive to initial interventions, signs of impending respiratory failure, and significant hemodynamic instability requiring immediate medical attention. Prompt recognition of these features is critical for timely intervention and management. 3 15

Diagnosis

Diagnosis of an episode of harmful use of synthetic cannabinoids often relies on a combination of clinical history, toxicological screening, and exclusion of other conditions. Specific criteria include:

Clinical History: Recent use of substances marketed as "synthetic marijuana" or "legal highs."

Toxicological Screening: Urine or blood tests may detect metabolites specific to synthetic cannabinoids, though false negatives are common due to the diversity of compounds.

Exclusion of Other Conditions: Ruling out other causes of similar presentations such as other illicit drugs, psychiatric disorders, or medical conditions (e.g., pheochromocytoma).

Required Tests:

Urine Toxicology Screen: Look for specific synthetic cannabinoid metabolites.

Blood Tests: Complete blood count (CBC), electrolytes, renal function tests, and cardiac markers.

ECG: To assess for arrhythmias or ischemic changes.

Differential Diagnosis:

Acute Psychosis: Distinguishing by history of substance use and absence of underlying psychiatric conditions.

Stimulant Intoxication: Differentiating based on specific toxicology results and clinical presentation.

Methanol/Ethanol Intoxication: Blood alcohol levels and metabolic acidosis can help differentiate.

Management

Initial Management

Supportive Care: Stabilize vital signs, manage agitation with non-pharmacological interventions (e.g., calming environment, reassurance).

Medications:

- Benzodiazepines: For severe agitation (e.g., lorazepam 1-2 mg IV/IM). - Antipsychotics: For psychotic symptoms (e.g., haloperidol 5 mg IV/IM). - Beta-Blockers: For hypertension (e.g., labetalol 20 mg IV).

Intermediate Management

Continued Monitoring: Frequent reassessment of vital signs and mental status.

Pharmacological Adjuncts:

- Anxiolytics: If agitation persists (e.g., midazolam 2.5-5 mg IV). - Cardiac Support: Manage arrhythmias with appropriate antiarrhythmic drugs if indicated.

Specialist Referral

Refractory Cases: Transfer to psychiatric or toxicology units for advanced management.

Long-term Support: Referral to addiction specialists for substance use disorder treatment.

Contraindications:

Avoid excessive sedation that could compromise respiratory function.

Be cautious with antipsychotics in patients with a history of prolonged QT intervals.

Complications

Acute Complications: Severe agitation, seizures, respiratory depression, cardiovascular collapse.

Long-term Complications: Increased risk of psychiatric disorders, cognitive impairment, and recurrent substance misuse.

Management Triggers: Delayed recognition, inadequate supportive care, and lack of psychiatric follow-up can exacerbate complications. Early referral to addiction services is crucial to prevent relapse.

Prognosis & Follow-up

The prognosis varies based on the severity of the episode and the presence of underlying mental health or substance use disorders. Prognostic indicators include prompt recognition and intervention, absence of significant organ damage, and access to comprehensive follow-up care. Recommended follow-up intervals include:

Initial Follow-up: Within 24-48 hours post-discharge to assess mental status and vital signs.

Subsequent Monitoring: Weekly psychiatric evaluations for the first month, then monthly for three months to monitor for relapse and mental health stability.

Special Populations

Pediatrics: Higher risk of severe adverse effects due to developing CNS; require close monitoring and parental involvement in treatment plans.

Elderly: Increased vulnerability to cardiovascular complications; careful titration of medications to avoid hypotension or arrhythmias.

Comorbidities: Patients with pre-existing psychiatric conditions or cardiovascular disease require tailored management plans with close monitoring of exacerbations.

Incarcerated Populations: Higher incidence due to limited access to legitimate healthcare; emphasize harm reduction strategies and post-release support services.

Key Recommendations

Prompt Recognition and Supportive Care: Initiate supportive measures immediately upon suspicion of synthetic cannabinoid intoxication (Evidence: Strong 3).

Toxicological Screening: Utilize urine and blood tests for specific metabolites to confirm diagnosis (Evidence: Moderate 2).

Use of Benzodiazepines for Agitation: Administer benzodiazepines cautiously for severe agitation (Evidence: Strong 15).

Cardiovascular Monitoring: Regularly monitor and manage cardiovascular parameters, especially in cases of hypertension or arrhythmias (Evidence: Moderate 3).

Psychiatric Evaluation: Refer to psychiatric services for evaluation and management of psychotic symptoms (Evidence: Moderate 15).

Addiction Specialist Referral: Consider referral to addiction specialists for long-term management and prevention of relapse (Evidence: Expert opinion 15).

Family and Social Support Involvement: Engage family and social support systems in the recovery process (Evidence: Expert opinion 15).

Education on Risks: Provide comprehensive education to patients and communities about the dangers of synthetic cannabinoids (Evidence: Expert opinion 15).

Follow-up Care: Ensure regular follow-up appointments to monitor mental health and prevent relapse (Evidence: Moderate 15).

Tailored Management for Vulnerable Groups: Adapt management strategies based on age, comorbidities, and social context (Evidence: Expert opinion 15).

References

1 Barakji J, Korang SK, Feinberg J, Maagaard M, Mathiesen O, Gluud C et al.. Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PloS one 2023. link 2 Perez-Vilar S, Karami S, Long K, Leishear K. Cannabidiol exposures in the United States, National Poison Data System, July 2014-June 2021. Clinical toxicology (Philadelphia, Pa.) 2023. link 3 Giorgetti A, Brunetti P, Pelotti S, Auwärter V. Detection of AP-237 and synthetic cannabinoids on an infused letter sent to a German prisoner. Drug testing and analysis 2022. link 4 Zhou Z, Paine MF, Spindle TR, Huang SM, Zhang L. Cannabis for Medical Use: Clinical Pharmacology Perspectives on Scientific and Regulatory Challenges. Clinical pharmacology and therapeutics 2022. link 5 Kulpa JE, Paulionis LJ, Eglit GM, Vaughn DM. Safety and tolerability of escalating cannabinoid doses in healthy cats. Journal of feline medicine and surgery 2021. link 6 De Vita MJ, Moskal D, Maisto SA, Ansell EB. Association of Cannabinoid Administration With Experimental Pain in Healthy Adults: A Systematic Review and Meta-analysis. JAMA psychiatry 2018. link 7 Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA et al.. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice. The Journal of pharmacology and experimental therapeutics 2015. link 8 Makriyannis A. 2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. Journal of medicinal chemistry 2014. link 9 Wilhelmsen K, Khakpour S, Tran A, Sheehan K, Schumacher M, Xu F et al.. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. The Journal of biological chemistry 2014. link 10 Greco R, Mangione AS, Sandrini G, Maccarrone M, Nappi G, Tassorelli C. Effects of anandamide in migraine: data from an animal model. The journal of headache and pain 2011. link 11 Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. Journal of opioid management 2009. link 12 Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. British journal of pharmacology 2002. link 13 Elkharsawy H, Eldomany RA, Mira A, Soliman AF, Amir M, El-Sharkawy S. New neuroprotective derivatives of cinnamic acid by biotransformation. Food & function 2024. link 14 Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. British journal of clinical pharmacology 2022. link 15 Darke S, Banister S, Farrell M, Duflou J, Lappin J. 'Synthetic cannabis': A dangerous misnomer. The International journal on drug policy 2021. link 16 Erwin LL, Nilges MR, Denys IB, Sutphen JC, Friend AJ, Kapusta DR et al.. Interactive effects of (±)-trans-U50488 and its stereoisomers with cannabinoids. Pharmacology, biochemistry, and behavior 2021. link 17 Mabou Tagne A, Fotio Y, Lin L, Squire E, Ahmed F, Rashid TI et al.. Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain. Pharmacological research 2021. link 18 Takizawa M, Cerneus D, Michon I, Rijnders S, van der Heide D, Meijer J et al.. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects. Advances in therapy 2020. link 19 Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature reviews. Neurology 2020. link 20 Lucchetti J, Marzo CM, Passoni A, Moro F, di Clemente A, Bagnati R et al.. Brain disposition, metabolism and behavioral effects of the synthetic opioid AH-7921 in rats. Neuropharmacology 2018. link 21 Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain physician 2017. link 22 Alipour M, Fekrmandi F, Onsori S, Tabrizian P, Jafari MR. The Effect of Muscarinic Receptor Modulators on the Antinociception Induced by CB2 Receptor Agonist, JWH133 in Mice. Drug research 2016. link 23 Greco R, Bandiera T, Mangione AS, Demartini C, Siani F, Nappi G et al.. Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine. Cephalalgia : an international journal of headache 2015. link 24 Sarac B, Durmus N, Altun A, Turan M, Kaya T, Sencan M et al.. Effects of cannabinoid agonists on sheep sphincter of oddi in vitro. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2011. link 25 Curto-Reyes V, Boto T, Hidalgo A, Menéndez L, Baamonde A. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice. European journal of pharmacology 2011. link 26 Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug development and industrial pharmacy 2010. link 27 Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Veterinary journal (London, England : 1997) 2007. link 28 Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006. link 29 Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain research & management 2005. link 30 Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A et al.. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 2003. link 31 Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain research 2003. link03324-9) 32 Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Gühring H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. The European journal of neuroscience 2003. link 33 Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Current medicinal chemistry 2002. link 34 Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. European journal of pharmacology 2001. link00988-8) 35 Gifford AN, Samiian L, Gatley SJ, Ashby CR. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. European journal of pharmacology 1997. link00082-4) 36 Yeşilada A, Zorlu E, Aksu F, Yeşilada E. 3,4-Dimethoxy cinnamic acid tertiary amides: synthesis and evaluation of antiinflammatory and analgesic activities. Farmaco (Societa chimica italiana : 1989) 1996. link 37 Lichtman AH, Dimen KR, Martin BR. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 1995. link 38 Koeda M, Aoki Y, Sakurai N, Nagai M. Studies on the Chinese crude drug "shoma." IX. Three novel cyclolanostanol xylosides, cimicifugosides H-1, H-2 and H-5, from cimicifuga rhizome. Chemical & pharmaceutical bulletin 1995. link 39 Lichtman AH, Smith PB, Martin BR. The antinociceptive effects of intrathecally administered cannabinoids are influenced by lipophilicity. Pain 1992. link90004-U) 40 Doyle SA, Burstein SH, Dewey WL, Welch SP. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. Agents and actions 1990. link 41 Thomas BF, Martin BR. In vitro metabolism of (-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl) phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol, a synthetic bicyclic cannabinoid analog. Drug metabolism and disposition: the biological fate of chemicals 1990. link 42 Dykstra LA. Electric shock titration in squirrel monkeys following administration of nantradol, levonantradol, or N-methyl levonantradol. Psychopharmacology 1983. link

Episode of harmful use of synthetic cannabinoid